Drugs / BOCODEPSIN
BOCODEPSIN
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03931681 | May 2019 → Nov 2021 | cancer | OnKure, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05340621 | May 2022 → Jan 2025 | RASopathy, melanoma | OnKure, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BOCODEPSIN | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314581 ↗ |
| Known as | BOCODEPSIN BESYLATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314581 ↗ |
| Known as | Bocodepsina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314581 ↗ |
| Known as | Bocodepsine | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314581 ↗ |
| Known as | OKI-006 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314581 ↗ |
| Known as | OKI-179 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05340621 ↗ |
| Modality | Small molecule | — CHEMBL5314581 ↗ |
| Route | Oral | “Patients will take OKI-179 orally (PO)” NCT03931681 ↗ |